AtheroGenics Discontinues High Dose Of AGI-1067 In Diabetes Trial Due To Liver Toxicity
This article was originally published in The Pink Sheet Daily
Executive Summary
ANDES trial will continue to evaluate the 75 mg and 150 mg doses of AGI-1067 after termination of 300 mg dosing.